Committed to babies and their health
Clinically proven to improve health outcomes of critically ill preemies
Committed to scientific and clinical research in breast milk
Prolact Product Safety

Executive Management


Scott A. Elster

Chief Executive Officer

Mr. Elster has over 20 years of experience in the biosciences and financial sectors. His experience encompasses planning, finance and strategy development, supply chain, and operations. Most recently, Mr. Elster was director of operations and supply chain at Clinical Micro Sensors (CMS)- a Motorola Company. There, Mr. Elster successfully prepared operations for the company’s first commercial launch, including FDA approval of the GMP manufacturing facility. He led the quality control function, the manufacturing team and operational strategy development. His team was also responsible for materials and inventory management, as well as distribution and warehousing.

For over 13 years at Baxter, Mr. Elster’s management work was focused directly on plasma products worldwide. His roles included manager of strategic planning, business development, finance and strategy for the hyperimmune business unit, and director of global supply chain. Mr. Elster began his career at Deloitte and Touche as a financial statement auditor. He is a board member and past chairman of the board for Monrovia Growers.

Mr. Elster received his Bachelor of Science from California State University, Northridge, and his Master of Business from the Anderson Graduate School of Management at University of California at Los Angeles.


Scott Eaker

General Manager and Regulatory Affairs, Quality

Mr. Eaker is responsible for quality management, regulatory affairs, and laboratory operations for Prolacta Bioscience. He has over 20 years of experience in the bioscience and nutrition sectors. Mr. Eaker began his career in the microbiology laboratory at Baxter Healthcare’s first recombinant Factor VIII manufacturing facility. He supported the start-up of the bulk manufacturing and fill/finish operations, implemented numerous test protocols, led failure investigations, and rapidly became a supervisor of laboratory operations.

Mr. Eaker also held a role serving as the subject matter expert in the areas of microbiology and aseptic processing for Baxter’s Bioscience Division. In this position he was responsible for developing and deploying standardized quality systems across multiple biologic and medical device manufacturing facilities in the U.S. and Europe. Mr. Eaker has also been responsible for quality in the plasma fractionation area and ultimately served as director of quality technical support for the Bioscience Division.

Mr. Eaker received a Bachelor of Science degree in microbiology from the University of California at Davis.

Alan Kofsky, VP of Sales & Marketing, Prolacta  

Alan Kofsky

VP, Sales & Marketing

Mr. Kofsky began his 22 year career working for Mead Johnson’s Infant Nutritional Division. He has held senior sales and marketing positions at both start-up and turnaround companies, as well as at companies in rapid growth circumstances. As vice-president of sales at Whatman, Inc., Mr. Kofsky led three business units, Bioscience, OEM and Distributor Sales, and was instrumental in reviving the struggling microarray business.

Prior to Whatman, Mr. Kofsky spent 13 years at Baxter Healthcare where he held senior sales and marketing positions in the BioScience Division. He led the successful global launch of Gammagard S/D which is a biologic that is used to treat numerous immune disorders. He also directed the launch of Tisseel VH, a product used in the operating room for hemostasis, sealing, and gluing. Additionally, Mr. Kofsky served in a vital leadership role for the successful development of Baxter’s BioSurgery Division which sells and markets a variety of biologics for the hospital operating room.

Mr. Kofsky received his Master of Business Administration from Adelphi University in New York and received his undergraduate degree from the State University of New York at Stony Brook.


Martin L. Lee, Ph.D.

VP, Clinical Research and Development

Dr. Lee is responsible for all research and development activities at Prolacta Bioscience as well as the regulatory compliance function.

He is also Adjunct Professor in the School of Public Health at UCLA and Adjunct Professor of Internal Medicine, Charles R. Drew University of Science and Medicine. Dr. Lee is the author or co-author of over 200 scientific papers. He is a fellow of the Royal Statistical Society and member of the American Statistical Association, the Society for Clinical Trials, the Biometrics Society, and the international Society of Thrombosis and Hemostasis.

Dr. Lee received a Bachelor of Arts (1974) degree in mathematics (summa cum laude), Master of Science, (1975) and, Ph.D. (1979) degree in biostatistics from the University of California, Los Angeles. He has worked for more than 25 years in the pharmaceutical and biotech industries as head of clinical and regulatory functions for these organizations.

Victoria Niklas, MD, Chief Medical and Scientific Officer at Prolacta  

Victoria Niklas, MD

Chief Medical and Scientific Officer

Dr. Victoria Niklas, MD earned her Master’s Degree in Biochemistry and Molecular Biology from Harvard University and MD from Harvard Medical School. She went on to complete a residency in Pediatrics at the Children’s Hospital of Los Angeles and a fellowship in Perinatal and Neonatal Medicine at UCLA.

She is currently the Chief Medical and Scientific Officer at Prolacta Bioscience, where she leads the Research and Development team in developing next-generation products from human milk. She also continues to serve as a Professor of Pediatrics at the UCLA David Geffen School of Medicine and in the practice of neonatology at the Olive View UCLA Medical Center.

Victoria is passionate about uncovering therapeutic potentials in human milk and transforming that knowledge into meaningful solutions in health care. Prior to joining Prolacta, she served as the Director of the Neonatal Intensive Care Unit and Newborn Services at Nemours Children’s Hospital and subsequently at the Olive View–UCLA Medical Center. Dr. Niklas’ research has focused on neonatal gastrointestinal immunology and the role of breast milk in reducing infections and necrotizing enterocolitis in premature newborns. She has also been responsible for groundbreaking research on lactoferrin, a protein found in high abundance in breast milk, in reducing hospital acquired infections in preterm newborns.

Dr. Niklas is an experienced neonatologist, educator, mentor and a leader of neonatal intensive care. She is a recognized expert in neonatal intestinal immunology, mouse models of intestinal immune T cell development and in the role of the gut microbiome in the pathogenesis of necrotizing enterocolitis and other diseases that occur throughout life.

Aly Fuller, Vice President, Intellectual Property at Prolacta Bioscience  

Alyson (“Aly”) C. Fuller, JD, Ph.D.

Vice President, Intellectual Property

Dr. Aly Fuller has over a decade of experience as a patent agent/attorney working in the life sciences and pharmaceutical sectors. Prior to joining Prolacta in August 2017, Dr. Fuller served as outside counsel for the company for nearly 9 years during her tenure at Cooley LLP.

Aly’s practice at Cooley focused on a holistic approach to IP including not only the preparation and prosecution of domestic and international biotechnology and pharmaceutical patent applications, but also due diligence, EPO oppositions, USPTO Reexamination proceedings and the preparation of business-focused invalidity/non-infringement, freedom to operate and patentability opinions. Aly is quite skilled at building strategic IP assets and helping turn those assets into business opportunities including strategic partnerships, product acquisitions and capital transactions.

At Prolacta, Aly is responsible for the cultivation, maintenance, defense and enforcement of the company’s extensive intellectual property portfolio. Aly also plays key roles in the company’s research and development and business development teams.

In addition to her responsibilities at Prolacta, Aly also devotes significant time toward the pro bono representation of LGBTQ individuals fleeing persecution in their home countries and seeking asylum in the US.

Aly graduated, cum laude, from Gannon University with a Bachelor of Science in Biology, from Northwestern University with a Ph.D. in Immunology and cum laude from The Catholic University Columbus School of law with a JD. Aly is admitted to practice in Washington State, Washington, DC and before the United States Patent and Trademark Office.

David Dryer, CFO of Prolacta Bioscience Headshot  

David C. Dreyer, CPA

Chief Financial Officer

Mr. David C. Dreyer CPA has almost 30 years of accounting, financial, compliance and operating experience and expertise in the healthcare field and has extensive senior leadership experience. 

Previously Mr. Dreyer was Chief Financial Officer between March 2015 to January 2017 for BIOLASE, Inc. (NASDAQ:BIOL), a medical device company that develops, manufactures, and markets innovative lasers used in dentistry. Between 2010 to 2015, Mr. Dreyer served as Chief Financial Officer, Chief Operating Officer and Secretary of Patient Safety Technologies, which develops, markets and sells healthcare products relating to surgical safety, and was a former public reporting company (OTC: PSTX). Since March 2014, Patient Safety became a subsidiary of Stryker Corporation (NYSE: SYK).

Between 2004 to 2009, Mr. Dreyer was Chief Financial Officer of AMN Healthcare Services, Inc. (NYSE: AHS), which provides healthcare staffing in hospitals including physicians, travel nurses, and allied travel. From 1997 through 2004, Mr. Dreyer served as Chief Financial Officer and Chief Accounting Officer of Sicor, Inc. (formerly Nasdaq: SCRI), a manufacturer of complex pharmaceuticals with operations in the United States and internationally, which was acquired by Teva Pharmaceutical Limited in January 2004. Prior to joining Sicor, Mr. Dreyer served in related senior financial management positions within the pharmaceutical industry, working for Elan Corporation plc, Athena Neurosciences and Syntex Corporation. Mr. Dreyer is a Certified Public Accountant in California. Mr. Dreyer has also been a director of InfuSystem Holdings, Inc. (NYSE:INFU), a leading national provider of infusion pumps and related services, since April 2008, and also a director since September 2014 of Diplomat Pharmacy Inc., the nation’s largest independent specialty pharmacy company in the US.

Vincent Gaspar, VP, International  

Vincent Gaspar

VP, International

Vincent Gaspar is Vice President of International and leads the strategic direction and growth of the company outside the US and Canada. Mr. Gaspar has over two decades of experience in sales and marketing leadership within the medical device and industry healthcare service companies. Throughout his career, Mr. Gaspar has gained extensive experience in acquisitions and mergers. He also has a proven track record in commercial organization development and restructuring.

Since 2008 Vincent was with Terumo BCT as the Senior Vice President of Global Blood Center with responsibilities to lead the Asia-Pacific business based in Singapore. Prior to those responsibilities, he led the EMEA region for 5 years, including the integration of Caridian BCT with Terumo in EMEA.

He began his career at Beckman-Coulter in Belgium, then joined Valleylab (a division of Pfizer, acquired by Tyco HealthCare) to lead the business in the Middle East, Africa, and southern Europe region.

For 9 years, Mr. Gaspar led the EMEA region for Kimberly-Clark Health Care (now Halyard Health) as General Manager for 9 years. Subsequently, he relocated to the global headquarters in Roswell, Georgia, to form and lead the Global Strategic Marketing for Kimberly-Clark’s healthcare division.

Vincent earned his Master’s degree in Biotechnology from the Catholic University Louvain (UCL) in Belgium. 

Mark Hannon VP, Operations  

Mark Hannon

VP, Operations

Mr. Hannon is responsible for manufacturing operations at Prolacta Bioscience. He has more than 25 years of leadership experience, including 15 years in manufacturing and quality management in the biotechnology, medical, pharmaceutical and food industries. Prior to joining Prolacta, Mr. Hannon led the Hershey company’s second-largest manufacturing operation in the US region.

Mr. Hannon’s career in biotechnology started with Baxter Healthcare, where he held leadership roles in manufacturing, planning and purchasing operations associated with cGMP plasma fractionation, bulk suspension and formulation, sterile bulk preparation, aseptic filling, lyophilization, pasteurization and packaging of plasma derived products. His other roles at Baxter included quality director for a medical device operation, as well as director of manufacturing and plant manager at one of the largest contract manufacturing sites of sterile products (syringes, vials and cartridges) in North America.

Mr. Hannon is a graduate of the United States Military Academy at West Point. He served as a US Army Airborne Ranger Infantry Officer in roles ranging from platoon leader to company commander.

Joe Fournell Chief Information Officer  

Joseph Fournell

Chief Information Officer

Mr. Fournell has over a decade of experience in the field of operations and supply chain management in the high-tech and bioscience sectors. Throughout his career, he has held leadership roles in operations, manufacturing execution systems, forecasting, supply planning, process engineering, and logistics.

Most recently, Mr. Fournell served as director of global logistics for Baxter Bioscience. In this capacity, Mr. Fournell managed the transportation, warehousing, and distribution of over $3 billion of product globally. At Baxter Bioscience, he led strategy planning sessions for operations, regulatory, and human resources. In his prior role at Baxter Bioscience, he became the first certified Six Sigma Black Belt in the U.S., working on process improvements in the manufacturing and supply chain arena.

Mr. Fournell received a Bachelor of Science in Industrial Engineering at California Polytechnic State University, San Luis Obispo, with an emphasis on process engineering. He also received a Master of Science degree in Industrial Engineering at California Polytechnic State University, San Luis Obispo, with a focus on factory automation, funded from a grant through NASA-AMES and Raytheon.


Susan Neumann

VP, Milk Procurement

Ms. Neumann is responsible for milk collections and milk bank marketing and operations. She has over 18 years of experience in the healthcare industry in marketing, project management and contract relationship management. Susan began her Prolacta career in 2010 on a consultant basis, and she now manages all aspects of Prolacta’s milk collection efforts. Prior to coming to Prolacta, Susan was co-owner of a franchised home improvement company, where she was responsible for direct to consumer marketing, accounts payable/receivable, employee payroll, and many other office manager functions. Susan’s most recent corporate experience was as Director of Global Marketing at Baxter Bioscience, where she was responsible for strategic marketing for the immunoglobulin and antibody therapy area. Other experience at Baxter included corporate development supporting the biosurgical product line and hyperimmune product line and management of the relationship with the American Red Cross. Susan also worked at the Bushnell Division of Bauch & Lomb in marketing and at Cetus Corporation, a biotechnology company, as a laboratory associate.

Susan received her Bachelor of Science degree in Physiology at the University of California, Davis in 1984, and she received a Master in Business Administration at the University of Southern California in 1988.

John M Shields - VP Legal Affairs, General Counsel  

John M. Shields

VP Legal Affairs, General Counsel, and Corporate Secretary

Mr. Shields joined Prolacta as Vice President Legal Affairs, General Counsel and Corporate Secretary in 2015 after representing Prolacta as outside counsel since 2006. Mr. Shields oversees all legal matters for the company, both in the U.S. and internationally, including commercial and financing transactions, corporate and regulatory compliance, securities law, employment practices, board and stockholder matters, business development and litigation.

In the fifteen years prior to joining Prolacta, Mr. Shields’ counseled a variety of companies in the pharmaceutical, medical device, IT and heavy manufacturing industries. His career in private practice focused on public and private securities offerings, corporate governance, M&A and strategic commercial transactions, first at Fenwick & West in Silicon Valley and later as a corporate partner with Stradling Yocca Carlson & Rauth in Orange County, California.

Mr. Shields received his Bachelor of Arts degree in Political Science and Philosophy at Stanford University and his Juris Doctor from the University of Virginia, where he was Articles Editor for the Law Review and a Dillard Fellow and supported the University’s patent portfolio development working for the UVA Patent Foundation. Prior to his legal career, Mr. Shields was an analyst with Science Applications International Corporation (SAIC) in Washington, DC working for the U.S. Department of Defense and the Joint Staff on international security and defense policy issues.


David J Rechtman, M.D.

VP, Medical Affairs

Dr. Rechtman received his M.D. from State University of New York - Downstate Medical Center College of Medicine. Following a residency in internal medicine and a fellowship in infectious diseases he served on the faculty of SUNY-Health Science Center at Brooklyn while helping to establish and lead the multi-disciplinary AIDS care team at the affiliated Kings County Hospital.

Upon deciding to pursue a career in industry, Dr. Rechtman was employed at Baxter Healthcare Corporation’s Hyland Division where he was responsible for product safety for the entire product line and medical affairs for immunological and infectious disease products. While at Hyland, he was instrumental in popularizing a highly effective therapy for a serious complication of bone marrow transplantation, as well as helping to achieve new indications for existing products. Subsequently, Dr. Rechtman spent several years as Medical Director for Ribi Immunochem Research Inc. where he was the Medical Officer for the first phase III trial of a commercial therapeutic cancer vaccine, which was targeted against malignant melanoma. That product was subsequently successfully licensed in Canada. He also directed the team developing a product for the prevention of sepsis in high- risk patients.

For the better part of a decade, Dr. Rechtman provided consulting services to various pharmaceutical and biotech companies. These activities subsequently developed into a successful contract research organization that designed and ran clinical trials in the U.S. and abroad. Dr. Rechtman has been an invited speaker at professional gatherings in the U.S. and Europe, has published original research and written chapters for several textbooks, and has given guest lectures to undergraduate and graduate university students in the areas of infectious and immunological diseases and therapies and their development.

Follow Us!